Study Title

64Cu-SAR-BBN Positron Emission Tomography: A Phase 2 Study of Participants With PSMA-negative Biochemical Recurrence of Prostate Cancer.

Study Details

Description:

The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with PSMA-negative biochemical recurrence of prostate cancer following definitive therapy.

Sponsor:

Clarity Pharmaceuticals

Contacts:

Clarity Pharmaceuticals (Clarity Clinical)

clinicaltrials@claritypharmaceuticals.com

+61 0 2 9209 4037

Government Study Link:

NCT05407311 - Click here to see study on

ClinicalTrials.gov

Inclusion

• Histologically confirmed adenocarcinoma of prostate per original diagnosis and completed subsequent definitive therapy
• Negative or equivocal findings for PC
• Adequate liver function
• Estimated Glomerular Filtration Rate of 30 mL/min or higher.
• Suspected recurrence of prostate cancer (PC) based on rising Prostate specific antigen (PSA) after definitive therapy

Exclusion

•Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedure
• Ongoing treatment or treatment within 90 days of Day 0 with any systemic therapy

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

United States

XCancer - Omaha

17607 Gold Plaza, Omaha, Nebraska 68130, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.